U.S. FDA Approves Liquidia's YUTREPIA™ (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)

FDA's approval of YUTREPIA paves the way for prescribers to add a new treatment option for patients with PAH and PH-ILDYUTREPIA is designed to enhance deep-lung delivery with an easy-to-use device requiring low